Galux is a pioneering company in protein therapeutics design, offering a unique platform, GaluxDesign, which integrates artificial intelligence with physical principles to revolutionize the development of protein therapeutics. The platform enables de novo antibody design, known for its complexity, with unprecedented accuracy. Galux is dedicated to advancing AI-driven protein design for drug discovery, fostering collaborations with industry leaders to develop next-generation therapies for rare diseases and beyond. The company aims to reshape the future of medicine through innovative protein design technologies.